Clinical Trials Logo
  1. Home
  2. Crohn's Disease
  3. NCT00088062
  4. Details
NCT00088062 Clinical Trial

STA-5326 in Crohn's Disease Patients

Crohn's Disease Clinical Trial

Official title:
A Phase I/IIa Trial of STA-5326 in Crohn's Disease Patients With CDAI Scores of 220-450

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00088062
Other study ID # 5326-03
Secondary ID Crohn's DiseaseC
Status Completed
Phase Phase 1/Phase 2
First received July 19, 2004
Last updated June 23, 2005
Start date February 2004
Est. completion date November 2004

Study information
Verified date May 2005
Source Synta Pharmaceuticals Corp.
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the safety and tolerability of STA-5326 given once daily or twice daily to Crohn's Disease patients with moderate disease.

Recruitment information / eligibility
Status Completed
Enrollment 48
Est. completion date November 2004
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Patients 18-65 years old

- Crohn's Disease for 6 months

- CDAI scores between 220-450

- +/- 5-ASA, stable dose for > 2 weeks

- +/- Corticosteroids, less than or equal to 40 mg per day with a stable dose for 2 weeks

- +/- Infliximab with no treatment within 4 weeks

- +/- 6-Mercaptopurine, with a stable dose for 8 weeks

- +/- Antibiotics, with a stable dose for 2 weeks

Exclusion Criteria:

- Patients who have had methotrexate, cyclosporine, or other experimental drug within 3 months of screening

- Pregnancy, breast feeding

- History of total proctocolectomy with stoma. Previous ileocolectomy would not be a contraindication to the study

- Bowel obstruction

- Surgical bowel resection within 90 days

- Total parenteral nutrition (TPN), CYA, tacrolimus

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Drug:
• STA-5326

Locations
Country Name City State
United States Blair Gastroenterology Associates Altoona Pennsylvania
United States Advanced Clinical Research Institute Anaheim California
United States Boston Medical Center Boston Massachusetts
United States Brigham and Women's Hospital Boston Massachusetts
United States Massachusetts General Hospital Boston Massachusetts
United States Carolina Research Associates Charlotte North Carolina
United States Northwestern University Chicago Illinois
United States University of Chicago Chicago Illinois
United States Long Island Clinical Research Great Neck New York
United States Memphis Gastroenterology Group Memphis Tennessee
United States Nashville Medical Research Institute Nashville Tennessee
United States Venture Research Institute, LLC North Miami Beach Florida
United States West Hills GI Portland Oregon
United States Wake Research Associates Raleigh North Carolina
United States Rochester Institute for Digestive Diseases and Sciences, Inc Rochester New York
United States Heart of America Research Institute Topeka Kansas
United States Advanced Clinical Therapeutics Tucson Arizona
United States Shafran Gastoenterology Center Winter Park Florida

Sponsors (1)
Lead Sponsor Collaborator
Synta Pharmaceuticals Corp.

Country where clinical trial is conducted

United States, 

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03815851 - Relationship Between Prophylactic Drainage and Postoperative Complications (PPOI) in Crohn's Patients After Surgery N/A
Not yet recruiting NCT06100289 - A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease Phase 3
Completed NCT02883452 - A Phase I Study to Evaluate Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous in Patients With Active Crohn's Disease and Ulcerative Colitis Phase 1
Recruiting NCT04777656 - Use of Crohn's Disease Exclusion Diet on Top of Standard Therapy Versus Standard Therapy Alone in Unstable Pediatric Crohn's Disease Patients. Phase 3
Terminated NCT03017014 - A Study to Assess Safety and Effectiveness of Adalimumab for Treating Children and Adolescents With Crohn's Disease in Real Life Conditions
Recruiting NCT06053424 - Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Healthy Participants and Patients With Crohn's Disease Phase 1
Recruiting NCT05428345 - A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
Completed NCT02508012 - Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases N/A
Not yet recruiting NCT02858557 - The Effect of Diet on Microbial Profile and Disease Outcomes in Patients With Inflammatory Bowel Diseases N/A
Terminated NCT02882841 - MOlecular BIomarkers and Adherent and Invasive Escherichia Coli (AIEC) Detection Study In Crohn's Disease Patients N/A
Completed NCT03010787 - A First Time in Human Study in Healthy Volunteers and Patients Phase 1
Completed NCT02542917 - Home Versus Postal Testing for Faecal Calprotectin: a Feasibility Study
Terminated NCT02417974 - Prevention of Recurrence of Crohn's Disease by Fecal Microbiota Therapy (FMT) Phase 2
Active, not recruiting NCT02316678 - Patient Attitudes and Preferences for Outcomes of Inflammatory Bowel Disease Therapeutics N/A
Completed NCT02193048 - Prospective Evaluation of a Scoring System in Patients Newly Diagnosed With Crohn's Disease
Completed NCT02154425 - A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers Phase 1
Completed NCT02265588 - Healthy Approach to Physical and Psychological Problems in Youngsters With IBD (HAPPY-IBD). N/A
Completed NCT02197780 - Head-to-head Comparison of Two Fecal Biomarkers to Screen Children for IBD N/A
Recruiting NCT02395354 - Comparative Prospective Multicenter Randomized Study of Endoscopic Treatment of Stenosis in Crohn´s Disease N/A
Completed NCT01958827 - A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's Disease Phase 3